Gastroenterology Deal Benchmarks
Benchmark deal terms for inflammatory bowel disease, Crohn's, celiac disease, NASH/MASH, and other GI conditions. Gastroenterology deals benefit from large patient populations and evolving treatment paradigms. Benchmarks derived from 115 verified transactions.
115
Total Deals
$1.9B
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
61
license
31
acquisition
19
collaboration
3
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
FutureGen → AbbVie FG-M701 | license | $150M | $1.7B | Sep 2026 |
Simcere → Boehringer Ingelheim SIM0709 | license | $46M | $1.2B | Sep 2026 |
Simcere Pharmaceutical Group → Boehringer Ingelheim SIM0709 | license | $47M | $1.2B | Sep 2026 |
Quotient Therapeutics → Merck & Co. IBD target-discovery alliance | collaboration | $20M | $2.2B | Sep 2026 |
Hanmi Pharm. Co., Ltd. → Eli Lilly and Company Sonefpeglutide (HM15912) | license | $75M | $1.3B | May 2026 |
Telavant → Roche RVT-3101 (RO7790121) | acquisition | $7.0B | $7.0B | Apr 2026 |
Prometheus Biosciences → Merck tulisokibart (MK-7240) | acquisition | $11.0B | $11.0B | Apr 2026 |
Quotient Therapeutics → Merck & Co. | collaboration | $20M | $2.2B | Mar 2026 |
GSK → Alfasigma Linerixibat | license | $300M | $590M | Mar 2026 |
GSK → Alfasigma linerixibat | license | $300M | $690M | Mar 2026 |
Benchmark Your Gastroenterology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 115 verified gastroenterology transactions.
Gastroenterology Deal Benchmarking FAQ
How do IBD deal valuations compare across mechanisms?
IBD deal valuations vary significantly by mechanism. Anti-TL1A and S1P modulators are commanding the highest valuations in 2026 ($200M+ upfronts for clinical-stage assets), while anti-integrin follow-ons and IL-23 inhibitors see more moderate terms. Bispecific approaches targeting dual pathways represent the next wave of premium-valued IBD assets.
What is the current state of celiac disease deal-making?
Celiac disease has emerged as a high-interest GI indication following multiple Phase 2 readouts. With no approved therapies beyond a gluten-free diet, first-in-class assets are commanding premium terms. Licensing deals for clinical-stage celiac programs feature upfronts of $50M-$150M with total values exceeding $1B.
How are microbiome therapy deals structured?
Microbiome deals have matured from pure-platform plays to product-specific licensing. Following the first FDA-approved microbiome therapy, deals now feature more traditional structures with upfronts of $20M-$80M and milestone-heavy payment schedules tied to clinical and regulatory events, plus royalties of 8-15% on net sales.